New Search

If you are not happy with the results below please do another search

1121 search results for:

231

Tecan’s Phase Separator advances automation for liquid biopsy and biobanking

Tecan has unveiled its Phase Separator, an innovative liquid separation technology that promises to save time and improve accuracy in laboratory workflows. With specific applications in liquid biopsy and biobanking, its benefits will be felt in genomics, proteomics and across multiple disease areas, from oncology and neurodegenerative disease to metabolic disorders.

232

Gyros Protein Technologies introduces PurePep EasyClean Auto Kit for automated parallel peptide purification

Gyros Protein Technologies, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanolitre-scale immunoassays, has launched PurePep EasyClean (PEC) Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.

234

Sartorius and Repligen Corporation introduce integrated system with Biostat STR and XCell ATF for upstream process intensification

The life science group Sartorius and Repligen Corporation have launched of an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceuti­cal manufacturers. The Biostat STR now contains a fully compatible embedded XCell ATF hardware and software module offering […]

235

Waters launches XBridge Premier GTx BEH SEC Columns for gene therapy applications

Waters Corporation has introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters XBridge Premier GTx BEH SEC columns doubles the speed of measuring the potency and safety of AAVs. Combining the […]

237

Tillotts Pharma and TVM Capital Life Science form Mage Biologics to develop oral antibody therapy for ulcerative colitis

TVM Capital Life Science, a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma, will jointly invest up to US$28 million in the newly formed U.S.-based biotechnology company, Mage Biologics. TVM will invest with its fund TVM Life Science Innovation II SCSp (TVM LSI II) […]

238

Exothera to manufacture Meissa Vaccines’ paediatric RSV vaccine candidate for Phase 2 trials

Meissa Vaccines, a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with Exothera, a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO). Exothera delivers customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids. Under the agreement, Exothera will manufacture […]

240

NK:IO raises more funding to advance pioneering NK cell therapy

NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2 million (about US$1.5 million). This brings total equity financing to £3.2 million and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into […]